• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Tyra Biosciences Inc.

    3/6/26 4:28:06 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TYRA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)


    TYRA BIOSCIENCES, INC.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)




    Peter Kolchinsky
    RA Capital Management, L.P., 200 Berkeley Street, 18th Floor
    Boston, MA, 02116
    617.778.2500

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    03/04/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    RA Capital Management, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    12,266,575.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    12,266,575.00
    11Aggregate amount beneficially owned by each reporting person

    12,266,575.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    21.2 %
    14Type of Reporting Person (See Instructions)

    IA, PN



    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    Peter Kolchinsky
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    12,266,575.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    12,266,575.00
    11Aggregate amount beneficially owned by each reporting person

    12,266,575.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    21.2 %
    14Type of Reporting Person (See Instructions)

    HC, IN



    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    Rajeev Shah
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    12,266,575.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    12,266,575.00
    11Aggregate amount beneficially owned by each reporting person

    12,266,575.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    21.2 %
    14Type of Reporting Person (See Instructions)

    HC, IN



    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    RA Capital Healthcare Fund, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    10,259,291.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    10,259,291.00
    11Aggregate amount beneficially owned by each reporting person

    10,259,291.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    17.7 %
    14Type of Reporting Person (See Instructions)

    PN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.0001 par value per share
    (b)Name of Issuer:

    TYRA BIOSCIENCES, INC.
    (c)Address of Issuer's Principal Executive Offices:

    2656 State Street, Carlsbad, CALIFORNIA , 92008.
    Item 1 Comment:
    Item 1 of the Statement is amended and supplemented as follows: This Amendment No. 6 (this "Amendment No. 6" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on September 27, 2021, and amended on February 6, 2024, October 22, 2024, November 13, 2024, March 31, 2025 and June 6, 2026 (as amended, the "Statement") by the Reporting Persons. This Amendment No. 6 is being filed to report the dilution of the Reporting Persons' beneficial ownership in the Issuer's common stock and not as a result of any acquisition or disposition of securities by the Reporting Persons. Unless otherwise defined herein, capitalized terms used in this Amendment No. 6 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged.
    Item 2.Identity and Background
    (a)
    This Schedule 13D/A is being filed on behalf of RA Capital Management, L.P. ("RA Capital"), Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Fund"), who are collectively referred to herein as the "Reporting Persons." The agreement among the Reporting Persons to file this 13D/A jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended (the "Act"), is attached hereto as Exhibit 99.1. The Reporting Persons' ownership of the Issuer's securities includes (i) 10,259,291 shares of common stock held directly by the Fund; (ii) 442,721 shares of common stock held by a separately managed account (the "Account"); (iii) 1,496,613 shares of common stock held by RA Capital Nexus Fund, L.P. (the "Nexus Fund"); (iv) Pre-Funded Warrants exercisable for up to 1,538,457 shares of common stock held directly by the Fund; (v) Exchange Warrants exercisable for up to 1,000,000 shares of common stock held directly by the Fund; (vi) a total of 64,250 shares underlying vested stock options (right to buy), and 3,700 shares underlying stock options (right to buy) which shall vest within 60 days of this filing held by Dr. Jake Simson for the benefit of RA Capital. The Pre-Funded Warrants and the Exchange Warrants each contain a provision (collectively the "Beneficial Ownership Blocker") which precludes exercise of the warrants to the extent that, following exercise, the Fund, together with its affiliates and other attribution parties, would own more than 19.99% of the common stock outstanding. The Fund is currently prohibited from exercising the Pre-Funded Warrants and/or the Exchange Warrants by virtue of the Beneficial Ownership Blocker. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund and RA Capital Nexus Fund GP, LLC is the general partner of the Nexus Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr. Kolchinsky and Mr. Shah are the controlling persons. RA Capital serves as investment adviser for the Fund, the Account, and the Nexus Fund and may be deemed a beneficial owner, for purposes of Section 13(d) of the Act, of any securities of the Issuer held by the Fund, the Account, or the Nexus Fund. The Fund and the Nexus Fund have delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund's and the Nexus Fund's portfolio, including the shares of the Issuer's common stock reported herein. Because the Fund and the Nexus Fund have divested themselves of voting and investment power over the reported securities they hold and may not revoke that delegation on less than 61 days' notice, the Fund and the Nexus Fund disclaim beneficial ownership of the securities they hold for purposes of Section 13(d) of the Act and therefore disclaim any obligation to report ownership of the reported securities under Section 13(d) of the Act. As managers of RA Capital, Dr. Kolchinsky and Mr. Shah may be deemed beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by RA Capital. RA Capital, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of the securities reported in this Statement other than for the purpose of determining their obligations under Section 13(d) of the Act, and the filing of the Statement shall not be deemed an admission that either RA Capital, Dr. Kolchinsky or Mr. Shah is the beneficial owner of such securities for any other purpose.
    (b)
    The address of the principal business office of each of the Reporting Persons is 200 Berkeley Street, 18th Floor, Boston, MA 02116.
    (c)
    The Fund is a private investment vehicle. RA Capital provides investment management services to the Fund, the Account and the Nexus Fund. The principal occupation of Dr. Kolchinsky and Mr. Shah is investment management.
    (d)
    During the last five years, none of the Reporting Persons has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    See Item 6 of the cover pages.
    Item 5.Interest in Securities of the Issuer
    (a)
    Rows 11 and 13 of each Reporting Person's cover page to this Schedule 13D/A set forth the aggregate number of shares of common stock and percentages of the shares of common stock beneficially owned by such Reporting Person and are incorporated by reference. The percentage set forth in each row 13 is based upon the sum of (i) 53,867,115 shares of common stock outstanding as of February 25, 2026, as reported in the Issuer's Annual Report on Form 10-K filed with the SEC on March 2, 2026; and (ii) 4,000,000 shares of common stock issued in a block transaction pursuant to the Issuer's at-the-market offering program, as reported in the Issuer's Current Report on Form 8-K filed with the SEC on March 4, 2026, adjusted to give effect to stock options, Pre-Funded Warrants and Exchange Warrants, to the extent exercisable within 60 days hereof, as referenced herein.
    (b)
    Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D/A set forth the number of shares of common stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.
    (c)
    Except as set forth herein, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days: No. Price Per Transaction Purchaser Date Shares Share Vest Stock Option (Right to Buy) RA Capital 01/29/2026 1,850 (1) Vest Stock Option (Right to Buy) RA Capital 02/28/2026 1,850 (1) Vest Stock Option (Right to Buy) RA Capital 03/29/2026 1,850 (1)(2) Vest Stock Option (Right to Buy) RA Capital 04/29/2026 1,850 (1)(2) (1) This option represents a right to purchase a total of 22,200 shares of the Issuer's common stock, which began vesting on June 29, 2025 and vests in 12 equal monthly installments over one year, subject to Dr. Simson's continued service to the Issuer through each vesting date. These options have an exercise price of $9.25 per share. (2) Represents future vesting options within 60 days from the filing date of this Schedule 13D/A.
    (d)
    Except as set forth below, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer since the most recent amendment to this Schedule 13D/A.
    (e)
    Not applicable.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Reporting Persons' Schedule 13D/A filed with the SEC on June 6, 2025).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    RA Capital Management, L.P.
     
    Signature:/s/ Peter Kolchinsky
    Name/Title:By Peter Kolchinsky, Authorized Signatory
    Date:03/06/2026
     
    Peter Kolchinsky
     
    Signature:/s/ Peter Kolchinsky
    Name/Title:Peter Kolchinsky
    Date:03/06/2026
     
    Rajeev Shah
     
    Signature:/s/ Rajeev Shah
    Name/Title:Rajeev Shah
    Date:03/06/2026
     
    RA Capital Healthcare Fund, L.P.
     
    Signature:/s/ Peter Kolchinsky
    Name/Title:By RA Capital Healthcare Fund GP, LLC, its General Partner, By Peter Kolchinsky, Manager
    Date:03/06/2026
    Get the next $TYRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TYRA

    DatePrice TargetRatingAnalyst
    2/24/2026Overweight
    Cantor Fitzgerald
    2/10/2026Outperform
    William Blair
    1/28/2026$59.00Overweight
    Barclays
    9/3/2025$35.00Strong Buy
    Raymond James
    5/21/2025$33.00Overweight
    Piper Sandler
    1/7/2025$28.00Buy
    UBS
    10/18/2024$22.00 → $31.00Neutral → Buy
    BofA Securities
    8/15/2024$33.00Overweight
    Piper Sandler
    More analyst ratings

    $TYRA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Tyra Biosciences Inc.

    SCHEDULE 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

    3/6/26 4:28:06 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Tyra Biosciences Inc.

    8-K - Tyra Biosciences, Inc. (0001863127) (Filer)

    3/4/26 5:18:29 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Tyra Biosciences Inc.

    10-K - Tyra Biosciences, Inc. (0001863127) (Filer)

    3/2/26 4:27:10 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Discovery Officer Bensen Daniel sold $262,965 worth of shares (8,000 units at $32.87), decreasing direct ownership by 5% to 146,981 units (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    2/13/26 4:30:07 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Discovery Officer Bensen Daniel sold $228,186 worth of shares (8,000 units at $28.52), decreasing direct ownership by 5% to 154,981 units (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    1/20/26 4:30:13 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director More Robert J sold $250,000 worth of shares (10,000 units at $25.00) (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    12/19/25 9:00:04 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $1,664,700 worth of shares (163,287 units at $10.19) (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    6/16/25 8:06:50 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $1,904,002 worth of shares (186,850 units at $10.19) (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    6/11/25 7:44:50 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $11,751,304 worth of shares (1,211,198 units at $9.70) (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    6/6/25 4:43:19 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

    - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -- Interim Ph2 data readouts on track: SURF302 expected by end of 1H'26 and BEACH301 in 2H '26 -- Cash, cash equivalents and marketable securities of $256.0 million at Q4 2025; runway through at least 2027 -CARLSBAD, Calif., March 2, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full-year ended Dece

    3/2/26 4:05:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

    CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts have been accepted for presentation at the 2026 ASCO® Genitourinary (GU) Cancers Symposium (ASCO GU). The meeting is being held February 26-28, 2026, in San Francisco, California.Details of the poster presentations are below:Title: "ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial"Abstract Number: 809Session: Poste

    2/23/26 5:30:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences to Participate in Upcoming Investor Conferences

    CARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences:36th Annual Oppenheimer Life Sciences Healthcare ConferenceFormat: Virtual fireside chat and one-on-one investor meetingsPresentation Date/Time: Thursday, February 26, 2026 at 12:00pm ETLocation: Virtual46th Annual TD Cowen Healthcare ConferenceFormat: Hybrid presentation & fireside chat and one-on-one investor meetingsPresentation Date/Time: Wednesday, March 4t

    2/19/26 4:05:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Tyra Biosciences

    Cantor Fitzgerald initiated coverage of Tyra Biosciences with a rating of Overweight

    2/24/26 7:56:45 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    William Blair initiated coverage on Tyra Biosciences

    William Blair initiated coverage of Tyra Biosciences with a rating of Outperform

    2/10/26 8:03:00 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Tyra Biosciences with a new price target

    Barclays initiated coverage of Tyra Biosciences with a rating of Overweight and set a new price target of $59.00

    1/28/26 7:19:59 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

    SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

    12/6/24 9:30:49 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

    SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

    11/19/24 9:31:34 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

    SC 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)

    11/14/24 5:47:01 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Leadership Updates

    Live Leadership Updates

    View All

    Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer

    CARLSBAD, Calif., Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of two key members of its leadership team: Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer.  Together, Mr. Ashar and Ms. Faulds will be essential in advancing oral dabogratinib through global Phase 2 studies in skeletal dysplasia and urologic cancers and preparing for potential future pivotal Phase 3 studies. Mr. Ashar's appointment is effective immediately a

    12/1/25 8:00:00 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

    CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Adele Gulfo to its Board of Directors. Ms. Gulfo brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world's best-selling medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma. "Adele is one of the most accomplished drug developers in our industry, with nearly thirty years of global ex

    1/29/25 4:05:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

    -TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC- -First patient expected to be dosed in SURF302 in Q2 2025- CARLSBAD, Calif., Jan. 10, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical trial of TYRA-300 in low-grade, intermediate risk non-muscle invasive bladder cance

    1/10/25 8:00:00 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Financials

    Live finance-specific insights

    View All

    Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

    - Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety results across all QD doses, with infrequent FGFR2/FGFR1-associated toxicities - - Conference call scheduled for October 25th, 2024, at 8AM EDT - CARLSBAD, Calif., Oct. 24, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, ann

    10/24/24 6:21:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

    CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024, in Barcelona, Spain. Gary Ste

    10/23/24 4:05:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia

    - In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024--Conference call and webcast today, March 1st, at 8:00 am ET- CARLSBAD, Calif., March 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptors (FGFR) biology, today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Ima

    3/1/23 7:00:00 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care